drugset / Trial / NCT00110591
Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to determine the safety and tolerability of PRO 140, an investigational anti-HIV drug, administered via intravenous infusion. Study hypothesis: Single intravenous doses of PRO 140 can be safely administered to humans and will result in measurable concentrations of the product in serum.
Timeline
- Start
- 2004-04-16
- Primary completion
- 2005-11-07
- Completion
- 2008-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leronlimab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Leronlimab | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | Leronlimab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Leronlimab | Monoclonal antibody | 5 mg/kg | Intravenous |